NCT00273364View on ClinicalTrials.gov

Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study

PHASE2CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

November 16, 2005

Primary Completion Date

January 5, 2017

Study Completion Date

August 30, 2019

Conditions
Multiple Sclerosis
Interventions
PROCEDURE

Hematopoietic Stem Cell Therapy

After mobilization and harvest of stem cells, stem cells will be infused following conditioning regimen

DRUG

Standard treatment with a conventional drug

Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), or Gilenya (fingolimod)

Trial Locations (1)

60611

Northwestern University, Feinberg School of Medicine, Chicago

All Listed Sponsors
collaborator

Uppsala University

OTHER

collaborator

Sheffield Teaching Hospitals NHS Foundation Trust

OTHER

collaborator

University of Sao Paulo

OTHER

lead

Northwestern University

OTHER

NCT00273364 - Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study | Biotech Hunter | Biotech Hunter